SAINT LAURENT, Quebec, May 14, 2021 (GLOBE NEWSWIRE) IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films,…
SAINT LAURENT, Quebec, May 12, 2021 (GLOBE NEWSWIRE) IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it has entered into a second feasibility agreement (the “SFA”) with ATAI Life Sciences AG (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being developed for the treatment of treatment-resistant depression and other indications. The first feasibility agreement between the companies was signed in August 2020. That was followed in March 2021 by IntelGenx and atai announcing a strategic partnership, including a proposed equity investment in IntelGenx by atai, positioning IntelGenx as a leader within the novel therapeutics field of psychedelics and providing additional financial resources t
Small Hydropower Industry Analysis and 2021 Future Trends
infinityApril 26, 2021
Small Hydropower Market: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast to 2027
The global Small Hydropower Market analysis report focuses on a condensed main statistical overview for the industry, as it serves as a useful guide for navigating the market’s challenges. Market research covers a wide range of topics, including global distribution, business statistics, market size, and market forces that affect global contributions. The Small Hydropower market size report also looks at in-depth growth challenges, existing investment opportunities, market share by product form and application, key players engaged in the growth, and future market opportunities.
Heritage Cannabis Reports First Quarter 2021 Financial Results
“Heritage”
or the “Company”), today announced its financial results as at and for the three months ended January 31, 2021 (“
Q1 2021”). All figures are in Canadian dollars unless otherwise noted.
“As we have stated previously, first quarter results do not include the positive impacts of the Premium 5 acquisition given the transaction closed at the end of the quarter, nor does it include results from our initial medical launch which will begin later this month,” stated Clint Sharples, Chief Executive Officer of Heritage. “As we move forward, we expect to see continued acceleration in both our medical and recreational product divisions with the addition of Premium 5 starting to have a material effect in Canada. Additionally, with our imminent launch in the multi-billion dollar U.S. market, and continued growth from our Pura Vida and Purefarma brands we expect to be well posit